UBS raised the firm’s price target on West Pharmaceutical (WST) to $320 from $285 and keeps a Buy rating on the shares. Growth is getting back on track for West Pharmaceutical, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Reports Strong Q2 2025 Results
- West Pharmaceutical Services’ Earnings Call Highlights Strong Growth
- West Pharmaceutical rises 22.2%
- West Pharmaceutical price target raised to $350 from $275 at Evercore ISI
- Strong Growth Prospects and Margin Recovery Justify Buy Rating for West Pharmaceutical Services